Orphazyme to give oral explanation as EMA committee decision nears
![The European Medicines Agency's headquarters in Amsterdam | Photo: Rob Acket/EMA](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13762437.ece/ALTERNATES/schema-16_9/doc7jugzdl9m2cgwplkoyo.jpg)
At 16:00 CET on Wednesday Feb 23, 2022, Orphazyme will meet with the European Medicines Agency’s (EMA) special committee, the CHMP, to give a so-called ”oral explanation.”
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme gets investor backing for fundraising round
For subscribers
Orphazyme plans to resubmit FDA application in H2
For subscribers
Leo Pharma poaches Orphazyme CEO
For subscribers